Appendix 3G — Director's Options
Imagion Biosystems has announced Appendix 3G — FY20 Director's Options. Download the announcement.
Appendix 3G — Performance Rights and Performance Options
Imagion Biosystems has announced Appendix 3G — FY20 Performance Rights and Performance Options. Download the announcement.
Phase I Study Update: Submission for Ethics Approval Filed
Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems Limited gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (Shares) as well as 6,500,000…
Appendix 2A — IBXOA Options
Imagion Biosystems Limited announces Appendix 2A — IBXOA Options. Read the announcement.
Appendix 2A — Fully Paid Ordinary Shares
Imagion Biosystems Limited announces Appendix 2A — Fully Paid Ordinary Shares. Read the announcement.
Proposed Issue of Securities — IBXOA
Imagion Biosystems Limited announces the proposed issue of 1,500,000 options expiring 28 April, 2023. Read the announcement.
Proposed Issue of Securities — IBX
Imagion Biosystems Limited announces the proposed issue of 1,000,000 ordinary fully paid securities. Read the announcement.
Upcoming Release of Shares from Escrow
Imagion Biosystems Limited (ASX: IBX) (the Company) advises in accordance with Listing Rule 3.10A, that 2,500,000 Fully Paid Ordinary Shares will be…
Quarterly Activity Report and Appendix C
Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in…